CBD Shows Multi-Target Anti-Cancer Effects in Lab Studies

CBD exhibits multi-target anti-tumor effects including inhibiting proliferation, inducing apoptosis, suppressing metastasis, and remodeling the tumor microenvironment through immunomodulation. It shows synergistic effects in combination therapy, can alleviate cancer-related symptoms, and has a favorable safety profile. However, evidence is predominantly preclinical.

Systematic review integrating recent high-quality research on CBD's anti-tumor effects across cancer types. Analyzed mechanisms in tumor cell biology and tumor microenvironment, compared monotherapy vs. combination therapy, reviewed symptom management, and assessed nano-based delivery systems.

Cancer treatment desperately needs new approaches. CBD's ability to attack tumors through multiple mechanisms while being well-tolerated is encouraging, but the critical caveat is that nearly all evidence is from lab and animal studies — not human trials.

CBD's multi-target approach is particularly interesting because cancer cells often develop resistance to single-mechanism drugs. By attacking through multiple pathways simultaneously, CBD might complement existing treatments. Nano-delivery systems could overcome CBD's poor bioavailability.

Predominantly preclinical models — in vitro and animal studies. No standardized dosing for anti-cancer use. CBD bioavailability is poor without specialized delivery. Cancer types and models vary widely across studies. Risk of publication bias toward positive results.